| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 23/05/2024 | 14:34 | Business Wire | ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 22/05/2024 | 14:32 | Business Wire | ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award | NASDAQ:CDXC | ChromaDex Corporation |
| 08/05/2024 | 22:04 | Business Wire | ChromaDex Corporation Reports First Quarter 2024 Financial Results | NASDAQ:CDXC | ChromaDex Corporation |
| 08/05/2024 | 22:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CDXC | ChromaDex Corporation |
| 08/05/2024 | 22:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CDXC | ChromaDex Corporation |
| 30/04/2024 | 14:32 | Business Wire | ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement | NASDAQ:CDXC | ChromaDex Corporation |
| 25/04/2024 | 14:34 | Business Wire | ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® | NASDAQ:CDXC | ChromaDex Corporation |
| 24/04/2024 | 14:34 | Business Wire | ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 23/04/2024 | 14:32 | Business Wire | ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market | NASDAQ:CDXC | ChromaDex Corporation |
| 26/03/2024 | 13:32 | Business Wire | ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program | NASDAQ:CDXC | ChromaDex Corporation |
| 06/03/2024 | 22:04 | Business Wire | ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results | NASDAQ:CDXC | ChromaDex Corporation |
| 06/03/2024 | 22:01 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:CDXC | ChromaDex Corporation |
| 24/02/2024 | 03:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CDXC | ChromaDex Corporation |
| 21/02/2024 | 14:32 | Business Wire | ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 05/02/2024 | 14:32 | Business Wire | ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 | NASDAQ:CDXC | ChromaDex Corporation |
| 26/01/2024 | 22:08 | Business Wire | ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference | NASDAQ:CDXC | ChromaDex Corporation |
| 20/12/2023 | 15:04 | Business Wire | ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® | NASDAQ:CDXC | ChromaDex Corporation |
| 12/12/2023 | 16:30 | PR Newswire (US) | Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ | NASDAQ:CDXC | ChromaDex Corporation |
| 30/11/2023 | 14:34 | Business Wire | A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) | NASDAQ:CDXC | ChromaDex Corporation |
| 15/11/2023 | 14:32 | Business Wire | Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients | NASDAQ:CDXC | ChromaDex Corporation |
| 09/11/2023 | 14:32 | Business Wire | ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 | NASDAQ:CDXC | ChromaDex Corporation |
| 08/11/2023 | 22:02 | Business Wire | ChromaDex Corporation Reports Third Quarter 2023 Financial Results | NASDAQ:CDXC | ChromaDex Corporation |
| 01/11/2023 | 13:34 | Business Wire | ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide | NASDAQ:CDXC | ChromaDex Corporation |
| 31/10/2023 | 13:34 | Business Wire | ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 | NASDAQ:CDXC | ChromaDex Corporation |
| 26/10/2023 | 14:32 | Business Wire | ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line | NASDAQ:CDXC | ChromaDex Corporation |
| 02/10/2023 | 14:32 | Business Wire | A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients | NASDAQ:CDXC | ChromaDex Corporation |
| 07/09/2023 | 12:20 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:CDXC | ChromaDex Corporation |
| 24/08/2023 | 14:32 | Business Wire | Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN | NASDAQ:CDXC | ChromaDex Corporation |
| 09/08/2023 | 22:02 | Business Wire | ChromaDex Corporation Reports Second Quarter 2023 Financial Results | NASDAQ:CDXC | ChromaDex Corporation |
| 08/08/2023 | 14:34 | Business Wire | ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness | NASDAQ:CDXC | ChromaDex Corporation |